Folotyn Approval History

• FDA approved: Yes (First approved September 24th, 2009)
• Brand name: Folotyn
• Generic name: pralatrexate
• Company: Allos Therapeutics, Inc.
• Treatment for: Non-Hodgkin's Lymphoma

Folotyn (pralatrexate) is a folate analogue metabolic inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

FDA Approval History for Folotyn

Date	Article
Sep 25, 2009	FDA Approves Folotyn (pralatrexate) for Treatment of Peripheral T-cell Lymphoma
Sep  3, 2009	Allos Therapeutics Announces FDA Advisory Committee Recommends Accelerated Approval of Folotyn (pralatrexate) for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Aug 11, 2009	Allos Therapeutics Announces FDA Advisory Committee to Review Pralatrexate for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Mar 25, 2009	Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

See also...

Folotyn (pralatrexate) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.